Abstract
Hepatocellular carcinoma (HCC) is the fifth most common cancer and the second leading cause of cancer mortality worldwide. Heterogeneity of clinical conditions contributes to the complex management of care for patients with advanced HCC. Recently, the treatment landscape for advanced HCC has expanded rapidly, with the additional FDA approvals of several oral tyrosine kinase inhibitors (lenvatinib, regorafenib, and cabozantinib), as well as immunotherapies such as immune check point inhibitors (nivolumab and pembrolizumab) and the monoclonal IgG1 antibody, ramucirumab. This expansion has generated a need for novel treatment sequencing strategies in this patient population. In light of these developments, an evaluation of the impact of FDA-approved therapeutics on patient-centered outcomes such as health-related quality of life (HRQoL) is warranted. An increased understanding of HRQoL in patients included in advanced HCC clinical trials could potentially help physician decision-making for treatment sequencing in patients with advanced HCC.
| Original language | English (US) |
|---|---|
| Article number | 841 |
| Journal | Cancers |
| Volume | 11 |
| Issue number | 6 |
| DOIs | |
| State | Published - Jun 2019 |
Fingerprint
Keywords
- Hepatocellular carcinoma
- Quality of life
- Systemic therapy
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
Current treatment landscape for advanced hepatocellular carcinoma : Patient outcomes and the impact on quality of life. / Li, Daneng; Sedano, Sabrina; Allen, Rebecca; Gong, Jun; Cho, May; Sharma, Sunil.
In: Cancers, Vol. 11, No. 6, 841, 06.2019.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Current treatment landscape for advanced hepatocellular carcinoma
T2 - Patient outcomes and the impact on quality of life
AU - Li, Daneng
AU - Sedano, Sabrina
AU - Allen, Rebecca
AU - Gong, Jun
AU - Cho, May
AU - Sharma, Sunil
PY - 2019/6
Y1 - 2019/6
N2 - Hepatocellular carcinoma (HCC) is the fifth most common cancer and the second leading cause of cancer mortality worldwide. Heterogeneity of clinical conditions contributes to the complex management of care for patients with advanced HCC. Recently, the treatment landscape for advanced HCC has expanded rapidly, with the additional FDA approvals of several oral tyrosine kinase inhibitors (lenvatinib, regorafenib, and cabozantinib), as well as immunotherapies such as immune check point inhibitors (nivolumab and pembrolizumab) and the monoclonal IgG1 antibody, ramucirumab. This expansion has generated a need for novel treatment sequencing strategies in this patient population. In light of these developments, an evaluation of the impact of FDA-approved therapeutics on patient-centered outcomes such as health-related quality of life (HRQoL) is warranted. An increased understanding of HRQoL in patients included in advanced HCC clinical trials could potentially help physician decision-making for treatment sequencing in patients with advanced HCC.
AB - Hepatocellular carcinoma (HCC) is the fifth most common cancer and the second leading cause of cancer mortality worldwide. Heterogeneity of clinical conditions contributes to the complex management of care for patients with advanced HCC. Recently, the treatment landscape for advanced HCC has expanded rapidly, with the additional FDA approvals of several oral tyrosine kinase inhibitors (lenvatinib, regorafenib, and cabozantinib), as well as immunotherapies such as immune check point inhibitors (nivolumab and pembrolizumab) and the monoclonal IgG1 antibody, ramucirumab. This expansion has generated a need for novel treatment sequencing strategies in this patient population. In light of these developments, an evaluation of the impact of FDA-approved therapeutics on patient-centered outcomes such as health-related quality of life (HRQoL) is warranted. An increased understanding of HRQoL in patients included in advanced HCC clinical trials could potentially help physician decision-making for treatment sequencing in patients with advanced HCC.
KW - Hepatocellular carcinoma
KW - Quality of life
KW - Systemic therapy
UR - http://www.scopus.com/inward/record.url?scp=85069640706&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85069640706&partnerID=8YFLogxK
U2 - 10.3390/cancers11060841
DO - 10.3390/cancers11060841
M3 - Review article
AN - SCOPUS:85069640706
VL - 11
JO - Cancers
JF - Cancers
SN - 2072-6694
IS - 6
M1 - 841
ER -